Christian Marth

Innsbruck Medical University — Austria

Medicine · Health Sciences

84h-index34.3kcitations810works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(298), Endometrial and Cervical Cancer Treatments(110), PARP inhibition in cancer therapy(88), Estrogen and related hormone effects(70), Epigenetics and DNA Methylation(64)

Publications802 total

JARID1A is associated with improved prognosis in epithelial high-grade ovarian cancer
2026Open Access
The Role of Plasmacytoid Dendritic Cells in the Immune Contexture of TP53-Mutated High-Grade Serous Ovarian Cancer
Cancers·2025Open Access
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Journal of Clinical Oncology·2025· 1 cited
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
International Journal of Gynecological Cancer·2025· 1 cited
FIRST-LINE LENVATINIB + PEMBROLIZUMAB VERSUS CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER: ADDITIONAL 1-YEAR FOLLOW-UP RESULTS FROM ENGOT-EN9/LEAP-001
International Journal of Gynecological Cancer·2025Open Access
A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107)
International Journal of Gynecological Cancer·2025
TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
International Journal of Gynecological Cancer·2025
TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer
Gynecologic Oncology·2025
page 1 of 41Next →

Frequent Co-authors

Ignace Vergote(18), Nicoletta Colombo(14), Mansoor Raza Mirza(12), Jonathan A. Ledermann(11), Domenica Lorusso(11), Antonio González-Martı́n(11), Carien L. Creutzberg(11), Martin Widschwendter(11), Jalid Sehouli(10), David Cibula(9), Denis Querleu(9), Heidi Fiegl(9), Elisabeth Müller‐Holzner(9), Tjalling Bosse(8), Isabelle Ray‐Coquard(8), Nicole Concin(7), Philippe Morice(7), Remi A. Nout(7), Alain G. Zeimet(7), Philipp Harter(7)